Abstracts tagged "outcomes and pediatrics"

Abstract Number: 464 • 2018 ACR/ARHP Annual Meeting
The Long Term Outcomes in Chinese Children Diagnosed with Systemic Lupus Erythematosus and Biopsy Proven Lupus Nephritis – a 18-Year Cohort
Grace Chiang^1,2, Sik Nin Wong³, Clara Law⁴, Kwok Piu Lee⁵, Cheuk Chun Szeto⁶, Chi Chiu Mok⁷, Lai-Shan Tam⁸ and Ting Fan Leung⁹, ¹Paediatrics, Prince of Wales Hospital, The Chinese University of Hong Kong, Sha Tin, Hong Kong, ²Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ³Paediatrics and Adolescent Medicine, Tune Mun Hospital, Hong Kong, Hong Kong, ⁴Medicine and Therapeutics, Alice Ho Miu Ling Nethersole Hospital, Hong Kong, Hong Kong, ⁵Paediatrics and Adolescent Medicine, Pamela Youde Nethersole Eastern Hospital, Hong Kong, Hong Kong, ⁶Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ⁷Medicine and Geriatrics, Tune Mun Hospital, Hong Kong, Hong Kong, Hong Kong, ⁸Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, Hong Kong, Hong Kong, ⁹Paediatrics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: Renal disease occurs in 50-70% of all childhood onset systemic lupus erythematosus (cSLE). The prevalence of LN is higher in children and the manifestations…
Abstract Number: 1419 • 2018 ACR/ARHP Annual Meeting
Long-Term Outcome of 50 Patients with Linear Scleroderma Treated with Methotrexate
Giorgia Martini¹, Gloria Fadanelli¹, Anna Agazzi¹, Fabio Vittadello¹, Alessandra Meneghel² and Francesco Zulian², ¹Department of Woman and Child Health, University of Padua, Padua, Italy, ²University of Padua, Department of Woman and Child Health, Padua, Italy
Background/Purpose: Linear Scleroderma (LS) is the most common subtype of localized Scleroderma in children and the one most frequently associated with tissue damage and functional…
Abstract Number: 27 • 2017 Pediatric Rheumatology Symposium
Assessing the Safety of Kidney Biopsies Performed on Childhood-onset Systemic Lupus Erythmatosus Patients
Shreya Goyal¹, Daniel Ashton^2,3, Kamlesh Kukreja^3,4, Michael C. Braun^5,6 and Scott E. Wenderfer^5,7, ¹Pediatrics, Baylor College of Medicine, Houston, TX, ²Interventional Radiology, Texas Children's Hospital, Houston, TX, ³Radiology, Baylor College of Medicine, Houston, TX, ⁴Interventional RAdiology, Texas Children's Hospital, Houston, TX, ⁵Texas Children's Hospital, Houston, TX, ⁶Pediatrics-Renal, Baylor College of Medicine, Houston, TX, ⁷Pediatrics-Renal, Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Title: Assessing the Safety of Kidney Biopsies Performed on Childhood-onset Systemic Lupus Erythematosus Patients Background/Purpose: There is very little data in the literature on…
Abstract Number: 392 • 2015 ACR/ARHP Annual Meeting
From Childhood to Adulthood: Longitudinal Trajectory of Damage in Patients with Childhood-Onset Systemic Lupus Erythematosus (cSLE)
Lily Siok Hoon Lim^1,2,3,4, Eleanor Pullenayegum⁵, Lillian Lim⁶, Dafna Gladman⁷, Brian Feldman⁸ and Earl Silverman⁹, ¹Institute of Health Policy Management and Evaluation, University of Toronto, Toronto, ON, Canada, ²Rheumatology, SickKids, Toronto, ON, Canada, ³Rheumatology, Hospital for Sick Children, Toronto, ON, Canada, ⁴Children's Hospital Research Institute of Manitoba, University of Manitoba, Winnipeg, MB, Canada, ⁵Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON, Canada, ⁶Pediatrics, The Hospital for Sick Children, Toronto, ON, Canada, ⁷Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁸Division of Rheumatology, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ⁹Division of Rheumatology, Hospital for Sick Children and University of Toronto, Toronto, ON, Canada
Background/Purpose: Outcomes of patients with cSLE over time and into adulthood are poorly understood. There has been no information about the longitudinal trajectory of organ…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].